drugset / Trial / NCT01925144

A Study of Baricitinib and Omeprazole in Healthy Participants

NCT01925144

Phase 1 Completed 30 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to find out how the body will react to a study drug called baricitinib when taken with another drug called omeprazole. For each participant, this study will include 2 periods in fixed order. The study will last approximately 25 days, not including screening.

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 10 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral

Indications

No indication recorded.